Spotlight on – The Future of Oncology Clinical Trials
We present the latest insight and analysis of the rapidly evolving field of cancer therapeutics and immuno-therapy, with a particular focus on what current innovation exists and means for the future of this critical area of medicine.
With a pipeline of as many as 600 oncology related treatments in the works, the next decade will see the pharmaceutical industry and its research partners face challenges in turning a range of promising scientific ideas into safe, effective medicines to extend the lives of cancer patients.
As tumour definitions become more granular, and treatments more specific and personalised, a new array of challenges are coming into view, central to which is evolving the clinical trial process, while remaining cost-effective.
Spotlight on the Future of Oncology Clinical Trials is a combination of resources jointly developed by pharmaphorum and QuintilesIMS to explore how these challenges can be met, by drawing on insights from QuintilesIMS’ experts. This includes in-depth discussion of the latest innovations, best new approaches to trial management, processes and technology to help focus decision-making and speed development times.
Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.
QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.
In the last two years, the first PD-1 checkpoint inhibitor drugs to reach patients have launched a revolution in cancer care.
Learn innovative solutions to address these challenges
Collaborate with CROs and sites to help minimize risks